Study of an oral drug for advanced squamous cell cancers
Treatments studied
Part of Cancer clinical trials.
This study tests an oral drug called ABBV-711, alone or with another drug, for adults with advanced squamous cell cancers of the head, neck, or lung that have stopped responding to standard treatments. It aims to see how safe and effective the drug is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer has progressed after trying standard treatments, or you cannot take those treatments.
- You must have a tumor sample (from a past biopsy or a new one) that can be tested.
- You cannot have an active autoimmune disease (except well-managed conditions like vitiligo, type 1 diabetes, or thyroid problems).
- You cannot have had chemotherapy, radiation, or other cancer treatments in the past 28 days (or less if the drug clears quickly).
- You cannot have taken certain strong medications (like some antibiotics or antifungals) or eaten grapefruit or Seville oranges in the last 2 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
This trial tests a drug called amivantamab, either alone or with other treatments, for people with head and neck cancer that has spread or come back. The goal is to see if the drug can help shrink tumors or control the cancer.
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
This study tests an experimental IV drug (ABBV-324) for adults with advanced liver cancer (HCC) or advanced squamous lung cancer (LUSC). It aims to see if the drug is safe and whether it can help control the disease.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This study collects blood and tumor tissue samples to analyze biological markers in patients with advanced head and neck squamous cell carcinoma before starting immunotherapy. The goal is to better understand how these markers relate to treatment response.
Hear when a new Advanced Squamous Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.